So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

On this episode of Fortune’s Leadership Next podcast, host Diane Brady talks to Eli Lilly chair ... with the scientific team ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Management also lowered the midpoint ... The Motley Fool Stock Advisor analyst team just identified what they believe are the ...

Despite the above, there are still a couple of silver linings that provide more than enough reason to be bullish about this stock.

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Regular meetings with company management allow the team to ... for roughly 10% of the strategy’s assets. The team remains bullish on Eli Lilly's leadership in the weight-loss market and believes ...

In all likelihood, when the management team at Eli Lilly and Company announces financial results for the third quarter of the 2024 fiscal year, that growth will be considered rather significant.

In addition to top-line figures that missed Wall Street expectations, management ... team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn ...